MX381725B - Medicamento que comprende anticuerpo anti-fosfolipasa d4. - Google Patents
Medicamento que comprende anticuerpo anti-fosfolipasa d4.Info
- Publication number
- MX381725B MX381725B MX2016001193A MX2016001193A MX381725B MX 381725 B MX381725 B MX 381725B MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 381725 B MX381725 B MX 381725B
- Authority
- MX
- Mexico
- Prior art keywords
- phospholipase
- present application
- pld4
- medicaments
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013158258 | 2013-07-30 | ||
| PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001193A MX2016001193A (es) | 2016-05-26 |
| MX381725B true MX381725B (es) | 2025-03-13 |
Family
ID=51493000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001193A MX381725B (es) | 2013-07-30 | 2014-07-30 | Medicamento que comprende anticuerpo anti-fosfolipasa d4. |
Country Status (17)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| PL3431504T3 (pl) * | 2012-01-31 | 2021-10-18 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| SG11201600666SA (en) * | 2013-07-30 | 2016-02-26 | Sbi Biotech Co Ltd | Medicament comprising anti-phospholipase d4 antibody |
| JP7316930B2 (ja) * | 2016-07-15 | 2023-07-28 | 武田薬品工業株式会社 | 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料 |
| EP3737702A1 (en) | 2018-01-12 | 2020-11-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型ｔｌｒ７の分析 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0752248T3 (da) * | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| EP1107978A1 (en) * | 1998-08-24 | 2001-06-20 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
| US20020146686A1 (en) * | 2000-12-07 | 2002-10-10 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
| JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
| PL3431504T3 (pl) * | 2012-01-31 | 2021-10-18 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| SG11201600666SA (en) * | 2013-07-30 | 2016-02-26 | Sbi Biotech Co Ltd | Medicament comprising anti-phospholipase d4 antibody |
-
2014
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 MX MX2016001193A patent/MX381725B/es unknown
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en not_active Ceased
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active Active
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016001193A (es) | 2016-05-26 |
| CN105745226A (zh) | 2016-07-06 |
| JP2019214621A (ja) | 2019-12-19 |
| CN105745226B (zh) | 2020-03-06 |
| WO2015016386A1 (en) | 2015-02-05 |
| RU2709741C2 (ru) | 2019-12-19 |
| TR201910330T4 (tr) | 2019-07-22 |
| BR112016002001A2 (pt) | 2017-08-29 |
| JP6431523B2 (ja) | 2018-11-28 |
| SG11201600666SA (en) | 2016-02-26 |
| DK3027656T3 (da) | 2019-08-05 |
| KR102367760B1 (ko) | 2022-02-24 |
| HUE044469T2 (hu) | 2019-10-28 |
| CA2919736A1 (en) | 2015-02-05 |
| AU2014297217A1 (en) | 2016-02-18 |
| AU2014297217B2 (en) | 2020-01-16 |
| BR112016002001B1 (pt) | 2023-04-25 |
| JP2016534022A (ja) | 2016-11-04 |
| PL3027656T3 (pl) | 2019-10-31 |
| KR20160034934A (ko) | 2016-03-30 |
| JP2019014759A (ja) | 2019-01-31 |
| RU2016106708A3 (cg-RX-API-DMAC7.html) | 2018-03-30 |
| RU2016106708A (ru) | 2017-09-01 |
| EP3027656A1 (en) | 2016-06-08 |
| JP6843449B2 (ja) | 2021-03-17 |
| CA2919736C (en) | 2022-03-22 |
| SG10201800592SA (en) | 2018-03-28 |
| EP3027656B1 (en) | 2019-06-26 |
| ES2736324T3 (es) | 2019-12-27 |
| US20160168266A1 (en) | 2016-06-16 |
| US20210130493A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201690503A1 (ru) | Антитела | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| MX381725B (es) | Medicamento que comprende anticuerpo anti-fosfolipasa d4. | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| EA201300133A1 (ru) | Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ | |
| CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
| UA122478C2 (uk) | Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1 | |
| EP2956126A4 (en) | FILM-FORMING PHARMACEUTICAL COMPOSITION FOR WOUND HEALING AND METHOD FOR THE MANUFACTURE THEREOF | |
| EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
| CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| MX2016001186A (es) | Diagnostico y terapia de cancer que implica celulas madre cancerosas. | |
| EA201300137A1 (ru) | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| MA40612A (fr) | Nouveaux anticorps anti-mfi2 et méthodes d'utilisation | |
| BR112016002401A8 (pt) | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| ECSP15002095A (es) | Formulación farmacéutica | |
| BR112016010336A2 (pt) | Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer | |
| ECSP13012481A (es) | Composiciones de anticuerpo anti-vegfr-3 | |
| BR112018015090A2 (pt) | anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |